Empowered Funds LLC Has $10.53 Million Holdings in Corteva, Inc. $CTVA

Empowered Funds LLC increased its holdings in Corteva, Inc. (NYSE:CTVA) by 36.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 125,758 shares of the company’s stock after purchasing an additional 33,475 shares during the quarter. Empowered Funds LLC’s holdings in Corteva were worth $10,527,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the stock. JPL Wealth Management LLC bought a new stake in shares of Corteva during the 3rd quarter valued at about $25,000. Garton & Associates Financial Advisors LLC bought a new stake in shares of Corteva in the 4th quarter valued at $27,000. Bank of Jackson Hole Trust bought a new stake in shares of Corteva in the 4th quarter valued at $28,000. Cornerstone Financial Management LLC acquired a new position in shares of Corteva during the 4th quarter valued at $29,000. Finally, Basepoint Wealth LLC acquired a new stake in Corteva in the fourth quarter worth $30,000. 81.54% of the stock is owned by institutional investors.

Corteva Stock Down 1.2%

CTVA opened at $89.39 on Friday. The company has a quick ratio of 1.03, a current ratio of 1.47 and a debt-to-equity ratio of 0.07. The stock has a market cap of $59.79 billion, a price-to-earnings ratio of 52.58, a PEG ratio of 2.74 and a beta of 0.56. Corteva, Inc. has a twelve month low of $60.53 and a twelve month high of $90.97. The company’s 50-day moving average price is $82.16 and its two-hundred day moving average price is $79.55.

Corteva (NYSE:CTVA) last issued its quarterly earnings results on Thursday, July 30th. The company reported $2.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.24 by $0.06. The company had revenue of $6.38 billion during the quarter, compared to analyst estimates of $6.60 billion. Corteva had a net margin of 6.50% and a return on equity of 9.95%. Corteva’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.20 EPS. Corteva has set its FY 2026 guidance at 3.600-3.800 EPS. As a group, equities analysts expect that Corteva, Inc. will post 3.76 earnings per share for the current year.

Corteva Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Tuesday, September 1st will be given a $0.18 dividend. This represents a $0.72 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Tuesday, September 1st. Corteva’s dividend payout ratio (DPR) is currently 42.35%.

Analyst Ratings Changes

Several research firms have recently commented on CTVA. Deutsche Bank Aktiengesellschaft boosted their price objective on Corteva from $90.00 to $100.00 in a report on Monday, May 11th. Bank of America upped their target price on shares of Corteva from $90.00 to $96.00 and gave the stock a “buy” rating in a research note on Monday, July 20th. CICC Research increased their target price on shares of Corteva from $80.00 to $93.00 and gave the company an “outperform” rating in a report on Wednesday, May 13th. Royal Bank Of Canada boosted their price target on shares of Corteva from $97.00 to $103.00 and gave the stock an “outperform” rating in a report on Tuesday, July 21st. Finally, UBS Group reduced their price objective on shares of Corteva from $90.00 to $86.00 and set a “neutral” rating for the company in a research report on Tuesday, June 9th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $90.19.

Key Headlines Impacting Corteva

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Quarterly earnings exceeded expectations: Corteva reported second-quarter EPS of $2.30, above the $2.24 consensus estimate and up from $2.20 a year earlier. Corteva Q2 Earnings Beat Estimates
• Positive Sentiment: Full-year outlook was raised: Management increased its 2026 EPS guidance to $3.60-$3.80, reflecting strong first-half performance, cost controls and growth from strategic platforms. The midpoint is broadly consistent with analyst expectations. Corteva Delivers Strong First Half and Raises Outlook
• Positive Sentiment: Growth initiatives remain supportive: Demand for newer seed germplasm, trait technologies and crop-protection products, along with licensing growth and operational improvements, helped offset competitive pricing pressure. Corteva also remains on schedule for the planned October 1 Vylor spin-off. Why Corteva’s Seed and Crop Protection Engines Matter
• Neutral Sentiment: Separation could reshape the investment story: Corteva’s innovation pipeline, including crop-protection products and royalty opportunities, may support future growth after the planned business split, although the benefits will depend on execution. Corteva’s Innovation Pipeline
• Negative Sentiment: Revenue missed expectations: Second-quarter revenue was $6.38 billion, below the $6.60 billion analyst estimate, and declined 1.2% year over year. Competitive pricing remains a concern. Corteva Earnings Press Release
• Negative Sentiment: Valuation and execution risks are elevated: After a powerful rally, CTVA trades near its 52-week high at a premium earnings multiple. Investors may remain cautious about separation costs, execution risk and whether growth can justify the valuation. Is CTVA Stock Worth Buying After Its Rally?

Corteva Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.